MOMENTA PHARMACEUTICALS INC Form 8-K February 02, 2009

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): January 27, 2009

Momenta Pharmaceuticals, Inc.

(Exact Name of Registrant as Specified in Charter)

Delaware (State or Other Jurisdiction of Incorporation) 000-50797 (Commission File Number) **04-3561634** (IRS Employer Identification No.)

675 West Kendall Street, Cambridge, MA (Address of Principal Executive Offices)

02142 (Zip Code)

(617) 491-9700

(Registrant s telephone number, including area code)

Not applicable

(Former Name or Former Address, if Changed Since Last Report)

| Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (<i>see</i> General Instruction A.2. below): | | | | | |
|--|--|--|--|--|--|
| o | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | | | | |
| o | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | | | | |
| o | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | | | | |
| o | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) | | | | |
| | | | | | |

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

(e)

On January 27, 2009, the Compensation Committee of the Board of Directors of Momenta Pharmaceuticals, Inc., a Delaware corporation (the Company), approved the following incentive cash bonuses and salary increases relating to performance during the fiscal year ended December 31, 2008 for the executive officers of the Company listed below:

| N | Name | Bonus | Salary Increase |
|---|----------------------------|---------------|-----------------|
| | Craig A. Wheeler | \$ 250,290 | 3% |
| | Richard P. Shea | \$ 78,133 | 4% |
| | Steven B. Brugger | \$ 130,857 | 4.5% |
| | John E. Bishop, Ph.D. | \$ 79,780 | 4.2% |
| | Ganesh Venkataraman, Ph.D. | \$ 84,189 | 4% |

2

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

MOMENTA PHARMACEUTICALS, INC.

Date: February 2, 2009 By: /s/ Craig A. Wheeler

Craig A. Wheeler

President and Chief Executive Officer

(Principal Executive Officer)

3